Recent clinical trials showed that survival outcomes were remarkably longer with cemiplimab, anti-PD-1 inhibitor, compared with single-agent chemotherapy for patients with recurrent cervical cancer following the first-line platinum treatment (Tewari et al., 2022). Here, PDCD1 is linked to cervical cancer.